Table 2.
Correlations of CINSARC classes with clinicopathological characteristics in Luminal B breast cancer patients.
| Characteristics | CINSARC classes | ||||
|---|---|---|---|---|---|
| N | Low-risk | High-risk | p-value | ||
| Patients’ age | 0.233 | ||||
| ≤50 | 283 | 104 (23%) | 179 (26%) | ||
| >50 | 843 | 345 (77%) | 498 (74%) | ||
| Pathological tumor type | 0.178 | ||||
| Ductal | 723 | 289 (80%) | 434 (81%) | ||
| Lobular | 76 | 26 (7%) | 50 (9%) | ||
| Other | 96 | 46 (13%) | 50 (9%) | ||
| Pathological grade | 3.13E−04 | ||||
| 1 | 65 | 35 (9%) | 30 (5%) | ||
| 2 | 427 | 198 (51%) | 229 (42%) | ||
| 3 | 446 | 156 (40%) | 290 (53%) | ||
| Pathological axillary lymph node status | 1.18E−02 | ||||
| Negative | 676 | 295 (60%) | 381 (52%) | ||
| Positive | 545 | 199 (40%) | 346 (48%) | ||
| Pathological tumor size | 0.322 | ||||
| pT1 | 398 | 169 (37%) | 229 (33%) | ||
| pT2 | 664 | 252 (55%) | 412 (59%) | ||
| pT3 | 91 | 38 (8%) | 53 (8%) | ||
| Adjuvant chemotherapy | 0.012 | ||||
| No | 880 | 375 (83%) | 505 (77%) | ||
| Yes | 230 | 77 (17%) | 153 (23%) | ||
| Adjuvant hormone therapy | 0.709 | ||||
| No | 457 | 188 (42%) | 269 (41%) | ||
| Yes | 647 | 258 (58%) | 389 (59%) | ||
| Follow-up median, months (min–max) | 1438 | 71 (0–243) | 63 (0–294) | 0.677 | |
| DFS event (%) | 1438 | 164 (28%) | 309 (36%) | 9.19E−04 | |
| 5-year DFS | 1438 | 79% [75–83] | 69% [66–73] | 2.01E−04 | |